Telix Pharmaceuticals Limited · ASX:TLX

Telix Pharmaceuticals — Fact Sheet (June 2023)

5 slides from Telix Pharmaceuticals's fact sheet, June 2023

  1. Slide 1: Changing the way we find and treat cancer and rare diseases

    Slide 1: Changing the way we find and treat cancer and rare diseases

    Changing the way we find and treat cancer and rare diseases Telix is an Australian-headquartered global healthcare business with international operations in Belgium, Japan, Switzerland, and the United States (U.S.). Telix’s targeted radiation imaging and therapy technologies have potential to transf

  2. Slide 2: Our technology: a global leader in radiopharmaceuticals

    Slide 2: Our technology: a global leader in radiopharmaceuticals

    Our technology A global leader in radiopharmaceuticals Telix is developing targeted radiation across the continuum from diagnosis Our point of difference: Theranostics for oncology and rare diseases and staging to treatment, both as stand-alone and “combination” therapies. harnessing the power Many

  3. Slide 3: Telix Manufacturing Solutions (TMS)

    Slide 3: Telix Manufacturing Solutions (TMS)

    Telix Manufacturing Solutions (TMS) The 2,800 sqm building includes a 965 sqm advanced radiopharmacy, with 9 clean rooms, Belgium has one of the highest concentrations of nuclear medicine equipment and specialists per 2 purification suites, 2 R&D laboratories, 2 quality control laboratories, 2 cyclo

  4. Slide 4: Snapshot and Board of Directors

    Slide 4: Snapshot and Board of Directors

    Snapshot Board of Directors ASX code Market capitalization Chairman H Kevin McCann AO TLX $3.7b Shares on issue 52 Week high/low MD/CEO $3.72 - $12.05 Dr Christian Behrenbruch $318.36m Date listed on ASX Market sector Non-Executive Directors 15 Nov 2017 Healthcare Dr Andreas Kluge All figures are in

  5. Slide 5: Speaker bios and Telix contacts

    Slide 5: Speaker bios and Telix contacts

    Speaker bios Dr Christian Behrenbruch Raphaël Ortiz Managing Director and Group CEO EMEA CEO Dr Behrenbruch has over twenty years of healthcare Raphaël has more than 20 years of pharmaceutical entrepreneurship and executive leadership experience. industry experience in a variety of roles, including

Source: Internet Archive copy of telixpharma.com

More decks from Telix Pharmaceuticals Limited

All 63 Telix Pharmaceuticals decks